The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

Some people of West African of descent face a higher risk of renal failure. New drugs based on gene research may help right ...

Trinasolar has received an International Design Excellence Award in the US, within the C&I product category, for its Vertex ...

One is that, also in our pain franchise ... And we intend to fully develop both of these markets at Vertex. We see them both as specialty markets. And longer-term, given the mechanism of action, we ...

Haystack, a leading modern intranet provider, today announced its collaboration with Google Cloud to integrate Google Cloud’s ...

Sometimes, complex technical achievements are best explained through one example. That's the approach Mete Atamel, Developer ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...